Gut decontamination by rifaximin in patients with predicted severe acute pancreatitis
Not Applicable
- Conditions
- Health Condition 1: K858- Other acute pancreatitis
- Registration Number
- CTRI/2021/11/037721
- Lead Sponsor
- Department of gastroenterology and heaptology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with a diagnosis of Predicted acute pancreatitis as per Atlanta classification presenting within seven days of pain onset
Patients with a diagnosis of Predicted acute pancreatitis as per Atlanta classification presenting within seven days of pain onset
Age >18 years
With one of the following:
1.Predicted Severe acute pancreatitis indicated by 3 or more points according to Imrie score
2.Atlanta classifification
3.and/or CECT Abdomen findings of Balthazar grade D or E
Exclusion Criteria
1.Previous history of allergy to Rifaximin
2.Patient with pancreatic malignancy
3.Postoperative pancreatitis after pancreatic surgery Bacteriologically proved infected necrosis at the time of randomization
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Development of infection of pancreatic necrosis documented by : <br/ ><br>â?¢Presence of gas on CECT or <br/ ><br>â?¢by positive culture from fine needle aspiration(FNA) in peri-pancreatic collection or <br/ ><br>â?¢Clinical deterioration or fever(38.5oC or 100.3oF) in absence of other explainable cause of infection (ie Pulmonary, UTI or Line infections) <br/ ><br>2. Mortality <br/ ><br>Timepoint: 1.Time of discharge <br/ ><br>2.till 12 weeks <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Duration of ICU or Hospital stay <br/ ><br>2.Development of organ failure <br/ ><br>Timepoint: 1. At discharge